A5012159520- COVID-19 Clinical Research Studies
- Streptococcal Infections and Treatments
- Infectious Diseases and Tuberculosis
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Infective Endocarditis Diagnosis and Management
- Autoimmune and Inflammatory Disorders Research
- Immunodeficiency and Autoimmune Disorders
- Inflammatory Myopathies and Dermatomyositis
- Vector-borne infectious diseases
- Dermatological and Skeletal Disorders
- Hepatitis B Virus Studies
- Tuberculosis Research and Epidemiology
- Glycogen Storage Diseases and Myoclonus
- Chronic Lymphocytic Leukemia Research
- Hepatitis C virus research
- Sarcoidosis and Beryllium Toxicity Research
- Antifungal resistance and susceptibility
- Hepatitis Viruses Studies and Epidemiology
- Central Venous Catheters and Hemodialysis
- Pneumocystis jirovecii pneumonia detection and treatment
- Vasculitis and related conditions
- Diagnosis and treatment of tuberculosis
- Drug-Induced Ocular Toxicity
- Viral Infections and Vectors
- Rabies epidemiology and control
Centre Hospitalier Universitaire de Bordeaux
2020-2024
Hôpital Pellegrin
2021-2024
Inserm
2018-2024
Institut Bergonié
2024
Hôpital Saint-André
2019-2023
University Hospital of Bern
2023
Université de Bordeaux
2020-2022
Centre Hospitalier Universitaire de Poitiers
2012-2019
Laboratoire de Génétique Cellulaire
2012
Clinical and laboratory predictors of COVID-19 severity are now well described combined to propose mortality or scores. However, they all necessitate saturable equipment such as scanners, procedures difficult implement blood gas measures. To provide an easy fast risk score upon hospital admission, keeping in mind the above limits, we sought for a scoring system needing limited invasive data simple test co-morbidity assessment by anamnesis. A retrospective study 303 patients (203 from...
Boffito et al . recalled the critical importance to correctly interpret protein binding. Changes of lopinavir pharmacokinetics in coronavirus disease 2019 (COVID‐19) are a perfect illustration. Indeed, several studies described that total plasma concentrations were considerably higher patients with severe COVID‐19 than those reported HIV. These findings have led reduction dose some patients, hypothesizing an inhibitory effect inflammation on metabolism. Unfortunately, changes binding never...
Combination therapy with hydroxychloroquine and darunavir/ritonavir or lopinavir/ritonavir has been suggested as an approach to improve the outcome of patients moderate/severe COVID-19 infection.To examine safety combination lopinavir/ritonavir.This was observational cohort study hospitalized for pneumonia treated lopinavir/ritonavir. Clinical evaluations, electrocardiograms pharmacokinetics hydroxychloroquine, darunavir lopinavir were examined according clinical practice...
old.There was a significant reduction in the median time to viral clearance with favipiravir (4 days; IQR " 2.5-9) compared lopinavir/ritonavir (11 8-13; P , 0.001).Further, by day 14, 91.4% of patients arm had radiographic improvement versus 62.2% arm.There significantly lower rate adverse events receiving (11.4% 55.6%; 0.01).Given demonstrated vitro activity against SARS-CoV-2 and signals benefit early clinical experience for COVID-19, further studies are urgently needed.The results...
Abstract Background Severe non-AIDS bacterial infections (SBIs) are among the leading causes of hospital admissions persons with human immunodeficiency virus (PWH) in regions high antiretroviral therapy coverage. Methods This large prospective cohort study PWH examined types infections, documentation, and evolution antibiotic resistance hospitalized SBIs over an 18-year period. Results Between 2000 2017, 459 had at least 1 SBI documentation. Among 847 SBIs, there were 280 cases bacteremia,...
Abstract Calcinosis is a complication of systemic sclerosis, most often occurring more than several years after diagnosis. We report the case man who developed severe calcinosis in shoulders and hips before other sclerosis' symptoms.